Clinical Trial

Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma

Unknown Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 21, 2023 (before its estimated November 2024 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to explore the effectiveness and safety of the combination of Anlotinib, Toripalimab, and albumin-bound paclitaxel with cisplatin for neoadjuvant therapy in resectable esophageal squamous cell carcinoma. The study aims to improve the pathological complete response rate (pCR), R0 resection rate, and disease-free survival (DFS) in patients undergoing esophageal cancer surgery. The findings of this study will provide guidance and new options for the treatment of locally advanced esophageal cancer patients.
Protocol Amendment History 1 change
critical Trial status changed: Not Yet Recruiting → Unknown 2026-08-09
Trial Details
NCT Number NCT05996484
Lead Sponsor Nanfang Hospital, Southern Medical University
Conditions Esophageal Carcinoma, Neoadjuvant Therapy
Enrollment 25 participants
Start Date 2023-09
Primary Completion 2024-11 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2023-08-21